Gain Therapeutics SA, of Lugano, Switzerland, said it received funding support from The Michael J. Fox Foundation for Parkinson's Research and The Silverstein Foundation for Parkinson's with GBA to advance its noncompetitive molecular chaperones for Parkinson's disease. The grant support recognizes the company's therapeutic approach for Parkinson's with mutations in the glucocerebrosidase (GBA) gene.